Medeon Biodesign Net Assets
Medeon Biodesign net assets. Based on the latest financial reports, Medeon Biodesign (6499) has net assets worth NT$1.27 Billion TWD (≈ $39.99 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.55 Billion ≈ $48.87 Million USD) and total liabilities (NT$282.14 Million ≈ $8.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Medeon Biodesign (6499) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.27 Billion |
| % of Total Assets | 81.81% |
| Annual Growth Rate | 0.03% |
| 5-Year Change | -63.31% |
| 10-Year Change | N/A |
| Growth Volatility | 29.82 |
Net Assets of Medeon Biodesign (2017–2025)
Net assets of Medeon Biodesign from 2017 to 2025. This chart illustrates how Medeon Biodesign's net assets have evolved over time, based on quarterly financial data. See Medeon Biodesign balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Medeon Biodesign (2017–2025)
The table below shows the annual net assets of Medeon Biodesign from 2017 to 2025. For live market cap and overall valuation, see Medeon Biodesign stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.54 Billion ≈ $48.42 Million |
+0.06% |
| 2024-12-31 | NT$1.54 Billion ≈ $48.39 Million |
-35.23% |
| 2023-12-31 | NT$2.37 Billion ≈ $74.72 Million |
-35.27% |
| 2022-12-31 | NT$3.66 Billion ≈ $115.42 Million |
-12.53% |
| 2021-12-31 | NT$4.19 Billion ≈ $131.96 Million |
+58.20% |
| 2020-12-31 | NT$2.65 Billion ≈ $83.41 Million |
+17.73% |
| 2019-12-31 | NT$2.25 Billion ≈ $70.85 Million |
+25.03% |
| 2018-12-31 | NT$1.80 Billion ≈ $56.66 Million |
+17.33% |
| 2017-12-31 | NT$1.53 Billion ≈ $48.29 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medeon Biodesign's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 124480200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Medeon Biodesign Net Assets Breakdown (December 2025)
Medeon Biodesign net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$3.19 Billion | 216.27% |
| Total Equity | NT$1.48 Billion | 100.00% |
Medeon Biodesign Competitors by Market Cap
The table below lists competitors of Medeon Biodesign ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Junee Limited Ordinary Shares
NASDAQ:JUNE
|
$226.20 Million |
|
Computer Modelling Group Ltd.
TO:CMG
|
$226.24 Million |
|
Polyram Plastic Industries Ltd
TA:POLP
|
$226.28 Million |
|
RGC Resources Inc
NASDAQ:RGCO
|
$226.31 Million |
|
Tong Ming Enterprise Co Ltd
TW:5538
|
$225.99 Million |
|
AC Immune Ltd
NASDAQ:ACIU
|
$225.94 Million |
|
Shenzhen HeKeda Precision Cleaning Equipment Co Ltd
SHE:002816
|
$225.94 Million |
|
BCEG Environmental Remediation Co. Ltd.
SHE:300958
|
$225.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medeon Biodesign's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,520,192,000 to 1,475,740,000, a change of -44,452,000 (-2.9%).
- Net loss of 668,062,000 reduced equity.
- New share issuances of 426,772,000 increased equity.
- Other factors increased equity by 196,838,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-668.06 Million | -45.27% |
| Share Issuances | NT$426.77 Million | +28.92% |
| Other Changes | NT$196.84 Million | +13.34% |
| Total Change | NT$- | -2.92% |
Book Value vs Market Value Analysis
This analysis compares Medeon Biodesign's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.47x to 4.86x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$21.33 | NT$74.00 | x |
| 2018-12-31 | NT$25.99 | NT$74.00 | x |
| 2019-12-31 | NT$27.40 | NT$74.00 | x |
| 2020-12-31 | NT$28.12 | NT$74.00 | x |
| 2021-12-31 | NT$56.64 | NT$74.00 | x |
| 2022-12-31 | NT$41.05 | NT$74.00 | x |
| 2023-12-31 | NT$25.21 | NT$74.00 | x |
| 2024-12-31 | NT$16.50 | NT$74.00 | x |
| 2025-12-31 | NT$15.22 | NT$74.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medeon Biodesign utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -159.28%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.21x
- Recent ROE (-45.27%) is below the historical average (-15.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -18.43% | -150.22% | 0.10x | 1.22x | NT$-381.84 Million |
| 2018 | 15.65% | 38.10% | 0.35x | 1.19x | NT$92.68 Million |
| 2019 | -13.07% | -57.74% | 0.18x | 1.26x | NT$-462.41 Million |
| 2020 | -9.42% | -29.47% | 0.20x | 1.62x | NT$-397.24 Million |
| 2021 | 50.32% | 3013.75% | 0.02x | 1.06x | NT$1.67 Billion |
| 2022 | -12.06% | -145.40% | 0.07x | 1.12x | NT$-793.50 Million |
| 2023 | -51.92% | -613.78% | 0.07x | 1.18x | NT$-1.44 Billion |
| 2024 | -52.99% | -275.10% | 0.16x | 1.24x | NT$-957.53 Million |
| 2025 | -45.27% | -159.28% | 0.24x | 1.21x | NT$-815.64 Million |
Industry Comparison
This section compares Medeon Biodesign's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,728,039,500
- Average return on equity (ROE) among peers: 11.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medeon Biodesign (6499) | NT$1.27 Billion | -18.43% | 0.22x | $226.02 Million |
| St.Shine Optical Co Ltd (1565) | $6.14 Billion | 8.90% | 0.26x | $143.27 Million |
| Maxigen Biotech Inc (1783) | $1.38 Billion | 13.83% | 0.15x | $99.19 Million |
| SciVision Biotech Inc (1786) | $1.02 Billion | -2.16% | 0.07x | $108.90 Million |
| Bioteque (4107) | $1.24 Billion | 13.88% | 0.36x | $228.15 Million |
| Chi Sheng Chemical (4111) | $1.22 Billion | 12.60% | 0.47x | $53.72 Million |
| BenQ Medical Technology (4116) | $1.12 Billion | 5.55% | 0.61x | $62.06 Million |
| Pacific Hospital Supply Co Ltd (4126) | $1.35 Billion | 25.50% | 0.22x | $172.69 Million |
| Bionime Corp (4737) | $1.07 Billion | 8.40% | 3.23x | $159.73 Million |
| Vizionfocus Inc. (4771) | $1.81 Billion | 12.94% | 0.60x | $388.43 Million |
| Formosa Optical Technology Co Ltd (5312) | $935.17 Million | 16.96% | 0.64x | $166.70 Million |
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more